Zacks Research Issues Optimistic Forecast for MMSI Earnings

Key Points

• Zacks Research raised its fiscal 2026 EPS estimate for Merit Medical Systems to $3.73 from $3.57, while forecasting EPS of $4.01 in 2027 and $4.32 in 2028. The 2026 estimate remains below the broader consensus of $3.81.
• Merit Medical recently reported quarterly EPS of $1.19, beating expectations of $0.96, on revenue of $418.84 million. Revenue rose 9.5% year over year, and management reaffirmed fiscal 2026 EPS guidance of $4.25 to $4.35.
• Analysts maintain a favorable outlook, with eight Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $100. However, the stock’s valuation near 37 times earnings and execution, tariff, product-launch, and acquisition risks could limit further upside.

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Equities research analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for Merit Medical Systems in a research note issued on Thursday, August 20th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $3.73 per share for the year, up from their previous estimate of $3.57. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.81 per share. Zacks Research also issued estimates for Merit Medical Systems' Q4 2026 earnings at $0.98 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, FY2027 earnings at $4.01 EPS, Q1 2028 earnings at $0.95 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.32 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.23. The company had revenue of $418.84 million during the quarter, compared to analysts' expectations of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.Merit Medical Systems's revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS.

A number of other analysts have also issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Merit Medical Systems from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Robert W. Baird set a $98.00 price target on shares of Merit Medical Systems in a research note on Friday, July 31st. Wells Fargo & Company lifted their price objective on shares of Merit Medical Systems from $74.00 to $83.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on shares of Merit Medical Systems from $77.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Barrington Research set a $114.00 target price on shares of Merit Medical Systems in a research note on Friday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $100.00.

Merit Medical Systems Stock Performance

MMSI stock opened at $90.28 on Tuesday. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The business's fifty day simple moving average is $77.88 and its two-hundred day simple moving average is $72.58. Merit Medical Systems has a twelve month low of $59.74 and a twelve month high of $94.75. The firm has a market cap of $5.39 billion, a price-to-earnings ratio of 37.31, a PEG ratio of 2.28 and a beta of 0.48.

Institutional Investors Weigh In On Merit Medical Systems

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its position in shares of Merit Medical Systems by 7.3% during the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier's stock worth $1,730,000 after buying an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Merit Medical Systems by 16.9% in the first quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier's stock worth $76,039,000 after acquiring an additional 103,878 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Merit Medical Systems by 745.9% in the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier's stock worth $86,000 after acquiring an additional 813 shares during the period. First Trust Advisors LP grew its holdings in Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier's stock worth $5,535,000 after acquiring an additional 11,770 shares in the last quarter. Finally, Cerity Partners LLC increased its position in Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier's stock valued at $282,000 after purchasing an additional 251 shares during the period. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Merit Medical Systems News Summary

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised multiple earnings forecasts. Estimates increased for fiscal 2026 EPS to $3.73 from $3.57, fiscal 2027 EPS to $4.01 from $3.82, and fiscal 2028 EPS to $4.32 from $4.12. Quarterly estimates were also increased for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, signaling expectations for improving profitability over the next several years.
• Positive Sentiment: The upgrades reinforce the company’s recent operating momentum. Merit’s latest reported quarter included revenue growth of 9.5% year over year and EPS of $1.19, well above the $0.96 analyst consensus, while management raised its fiscal 2026 EPS guidance to $4.25-$4.35.
• Positive Sentiment: Growth is being supported by product launches, acquisitions and a broader mix of therapeutic medical products. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
• Neutral Sentiment: Not all revisions were positive: Zacks trimmed its Q4 2026 EPS forecast slightly to $0.98 from $0.99. Its fiscal 2026 estimate of $3.73 also remains below the broader consensus forecast of $3.81.
• Negative Sentiment: Valuation and execution risks could limit further gains. Merit trades at roughly 37 times earnings, and analysts have flagged tariff exposure and the need to successfully execute its product and acquisition strategy after a 22.2% monthly rally. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source